Breaking News, Collaborations & Alliances

IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2

Leverage complementary expertise & capabilities with rVSV technology to advance vaccine candidate.

By: Contract Pharma

Contract Pharma Staff

Merck and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, are collaborating to develop an investigational vaccine against SARS-CoV-2 to be used for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s Ebola Zaire virus vaccine, ERVEBO (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Merck has ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters